Thursday, 27 October 2016

Alnylam Pharmaceuticals Market Consumption 2016 Forecast to 2022

The report provides comprehensive information on the therapeutics under development by Alnylam Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

- The report provides a snapshot of the pipeline therapeutic landscape of Alnylam Pharmaceuticals, Inc.
- The report provides overview of Alnylam Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Alnylam Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Alnylam Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy
- Evaluate Alnylam Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Alnylam Pharmaceuticals, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alnylam Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Alnylam Pharmaceuticals, Inc. Snapshot 6
Alnylam Pharmaceuticals, Inc. Overview 6
Key Information 6
Key Facts 6
Alnylam Pharmaceuticals, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Alnylam Pharmaceuticals, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Alnylam Pharmaceuticals, Inc. - Pipeline Products Glance 14
Alnylam Pharmaceuticals, Inc. - Late Stage Pipeline Products 14
Phase III Products/Combination Treatment Modalities 14
Alnylam Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Alnylam Pharmaceuticals, Inc. - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Discovery Products/Combination Treatment Modalities 18
Alnylam Pharmaceuticals, Inc. - Drug Profiles 19
patisiran 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
revusiran 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
ALN-PCSsc 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
fitusiran 25
Product Description 25
Mechanism of Action 25
R&D Progress 25

Contact Info:
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)                                                   

Get in touch:

No comments:

Post a Comment